Your search for non small cell lung cancer returned 31 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Brian Park, PharmD remove
Older than 2 years remove

Your search for non small cell lung cancer returned 31 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Cemiplimab Granted Priority Review for Advanced NSCLC

Topline results from the trial showed that compared with chemotherapy, treatment with cemiplimab-rwlc reduced the risk of death by 32% in the overall trial population.
Drugs in the Pipeline

Tepotinib Gets Priority Review for Metastatic NSCLC With METex14 Skipping Mutation

The Food and Drug Administration (FDA) has granted Priority Review to tepotinib (EMD Serono) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 (METex14) skipping, as detected by an FDA-approved test. The application is supported by data from the ongoing,…

Tecentriq Gains Approval for Additional Lung Cancer Indication

The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.